Modafinil as
Adjunct Therapy for Daytime Sleepiness in Obstructive Sleep Apnea.
Pack AI, Black JE, Schwartz JR, Matheson JK.
Center for Sleep and Respiratory Neurobiology,
University of Pennsylvania,
Philadelphia, Pennsylvania;
Stanford Sleep Disorders Clinic, Stanford,
California;
Integris Sleep Disorders Centers of Oklahoma, Oklahoma City,
Oklahoma; and Sleep Disorders Center, Beth Israel Deaconess Medical Center,
Boston, Massachusetts.
Am J Respir Crit Care Med 2001 Nov 1;164(9):1675-1681
Abstract:
Patients with obstructive sleep apnea/hypopnea
syndrome can experience residual daytime sleepiness despite regular use of nasal
continuous positive airway pressure therapy. This randomized, double-blind,
placebo-controlled, parallel group study assessed the efficacy and safety of modafinil
for the treatment of residual daytime sleepiness in such patients.
Patients received modafinil (n = 77) (200 mg/d, Week 1; 400 mg/d, Weeks 2 to 4)
or matching placebo (n = 80) once daily for 4 wk. Modafinil significantly
improved daytime sleepiness, with significantly greater mean changes from
baseline in Epworth Sleepiness Scale scores at Weeks 1 and 4 (p < 0.001) and
in multiple sleep latency times (MSLT) at Week 4 (p < 0.05). The percentage
of patients with normalized daytime sleepiness (Epworth score < 10) was
significantly higher with modafinil (51%) than with placebo (27%) (p < 0.01),
but not for MSLT (> 10 min; 29% versus 25%). Headache (modafinil, 23%;
placebo, 11%; p = 0.044) and nervousness (modafinil, 12%; placebo, 3%; p =
0.024) were the most common adverse events. During modafinil
or placebo
treatment, the mean duration of nCPAP use was 6.2 h/night, with no significant
change from baseline observed between groups. Modafinil may be a useful adjunct
treatment for the management of residual daytime sleepiness in patients with
obstructive sleep apnea/hypopnea syndrome who are regular users of nasal
continuous positive airway pressure therapy.
1. Modafinil for
sustaining the alertness of helicopter pilots
2. Modafinil augmentation
of antidepressant treatment
3. Modafinil the
unique properties of a new stimulant
4. Modafinil children
with attention-deficit/hyperactivity disorder
5. Modafinil dosage
and safety
6. Modafinil successful
treatment of hypersomnia & narcolepsy
7. Modafinil narcolepsy:
symptoms and management
8. Modafinil
amplification of cortical serotonin release
9. Modafinil
treatment of alcoholic organic brain syndrome
10. Modafinil
effect on melatonin, cortisol, and growth hormone
11. Modafinil
in obstructive sleep apnea-hypopnea syndrome
12. Modafinil
vs dextroamphetamine in treatment of adult ADHD
13. Modafinil
efficacy in narcolepsy
14. Modafinil
switching from narcolepsy drugs to modafinil
15. Modafinil
dopaminergic transmission mediates CNS stimulants
